Pfizer's New Platform Under Fire: Convenient Services Behind, User Health May Be Swallowed by Digital Divide!
Under the background of deepening the reform of the medical and health system and promoting the strategy of healthy China, Pfizer, the world's leading pharmaceutical company, actively expands its service model and innovates and launches a comprehensive service platform for consumers. The platform is designed to provide convenient telemedicine services to the general public, including assisting users to schedule telemedicine appointments, complete electronic prescription filling, and easily access Pfizer's drug savings programs for COVID-19, migraines, flu and other diseases. At the same time, the platform will also help the public arrange for important vaccination services such as pneumococcal pneumonia vaccine and respiratory syncytial virus vaccine.
Amir Malik, Pfizer's Chief Commercial Officer in the United States, stressed that the launch of the platform is an important step in the company's commitment to simplifying access to health care for people seeking a better and healthier life. Pfizer will continue to deepen collaboration with partners such as Upscript Thealth, Alto Pharmacy and Instacart to build a better healthcare delivery system.
It is worth mentioning that Pfizer has a wealth of experience in the field of pharmaceutical services, as early as 2011, its flagship product Lipitor cholesterol drug has launched mail order services to meet market demand. Going forward, Pfizer will further expand its service capabilities, but at this stage it will focus on providing convenient same-day appointments, whether online or offline, and ensuring timely distribution of medicines and diagnostic tests for diseases such as COVID-19 and influenza. The medicines will be delivered by Courier to the designated pharmacy or to the user.
In addition, the PfizerForAll platform will integrate all of Pfizer's drug savings plans to provide consumers with a one-stop service experience to help the general public more easily enjoy their own health benefits, thereby effectively improving the level of public health.
2026-10-16
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
BASF India to Shut Two Dahej Care Chemicals Plants as Overcapacity Squeezes Margins
-
LANXESS Specialty Additives Earnings Jump 32.8%, but Chemical Demand Recovery Remains Elusive
-
BASF Brings Biomass-Balance Polyols to North America
-
Production Down 6%, Profits Cut by $3.7 Billion: Middle East Conflict Hits ExxonMobil Hard
-
Wanhua Chemical's Hungarian 650,000-ton MDI/TDI Plant to Shut Down for 35-Day Maintenance
-
Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
-
DyStar Becomes a Wholly-Owned Subsidiary of Zhejiang Longsheng Group, Ending Longstanding Shareholder Disputes with a $5 Billion Deal
-
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
-
Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy
Recommend Reading
-
Glyphosate Becomes a Trade Fight
-
Profit Soars While Sales Dip: Syngenta Group Defies Headwinds with 28% EBITDA Surge in Q3 2025
-
The Crop Protection Patent Cliff Is Here
-
South Korea’s June Petrochemical Export Value Rises 18.8%, While Export Volume Falls 14.6%
-
Growing Pains, But the Roots Are Strong: Corteva Narrows Losses Amid Sales Surge in Q3 2025
-
Market Conditions Continue to Weaken; Melamine Remains in a Low Range
-
Geopolitical Conflicts and Tightening Inventories Push Oil Market Up 3% on Tuesday
-
Phosphate prices weakened and fell in the first week of July in China (7.1-7.7)
-
BDO Market Trend Consolidation and Operation
-
Business Society’s Market Outlook for DOP on September 7, 2026: Relatively Resilient with a Slight Bullish Bias